GRI Bio, Inc. (GRI)
GRI Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in La Jolla, CA, US. The stock last traded at $2.19, down 0.45% on the session, giving a market capitalisation of $196,732. On trailing twelve-month figures it carries a trailing P/E of -0.03, a net margin of 0.0%. Its beta of -0.66 implies it has historically moved less than the broad market.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Bio, Inc. is most often compared with the following Healthcare names: